Abstract
Pancreatic cancer is the eighth leading cause of cancer death and is difficult to treat because clinical presentation is often late, and the disease is resistant to conventional chemotherapy. About 57% of pancreatic cancer patients are diagnosed at distant metastasis status and five-year survival rate is only 2%. More than 90% of pancreatic cancer has activating mutations in KRAS and recent exome sequencing studies have identified additional mutations in several kinds of genes such as AIRD1A, ARID1B, SMARCA1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
